GCCL

Seoul – October 13, 2026 -- South Korea's GCCL and LabConnect signed a memorandum of understanding on October 12 to link their North American and Asia-Pacific (APAC) central laboratory capabilities for joint sales and project execution in global clinical trials.

Partners formalize a relationship spanning more than 20 years

The agreement builds on a collaboration that has run for more than 20 years. It aims to improve the operational efficiency of global trial projects by combining each company's regional expertise. Financial terms were not disclosed.

The signing took place at GCCL's headquarters. GCCL CEO Kwan-goo Cho attended, as did LabConnect's Jeff Mayhew, Founder and Strategic Commercial Advisor, and Joshua Gentile, Senior Vice President, Head of Commercial Sales and Marketing.

Yongin, South Korea – September 11, 2026 -- GCCL (Global Clinical Central Lab), a South Korea-based clinical trial sample analysis provider, sponsored the Asia Bio Partnering Forum 2026 (ABP 2026) as a Platinum Sponsor, using the Singapore event to pursue expansion of its assay development and clinical sample analysis services across the Asia-Pacific region.

GCCL held partnering meetings with drug developers across mRNA, radiopharmaceutical and antibody therapy segments

The forum, held in Singapore from August 31 to September 2, drew approximately 650 pharmaceutical and biotechnology industry professionals, investors and life sciences stakeholders, generating roughly 2,500 one-on-one partnering meetings. GCCL engaged drug developers working across mRNA and nucleic acid therapeutics, radiopharmaceuticals and antibody-based therapies to assess evolving analytical requirements in global clinical development.

Yongin, South Korea – September 11, 2026 -- GCCL (Global Clinical Central Lab), a South Korea-based clinical trial sample analysis provider, served as a Platinum Sponsor at the Asia Bio Partnering Forum 2026 (ABP 2026) in Singapore, held from August 31 to September 2, as it pursued expansion of its assay development and sample analysis services across the Asia-Pacific region.

ABP 2026 drew 650 industry professionals and 2,500 one-on-one partnering meetings

The forum brought together approximately 650 pharmaceutical and biotechnology executives, investors and life sciences stakeholders, with roughly 2,500 one-on-one partnering meetings held over three days. GCCL used the event to hold discussions with drug developers, contract research organizations (CROs) and regional stakeholders from Korea, China, Japan, Singapore, Vietnam and Europe.